<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03813394</url>
  </required_header>
  <id_info>
    <org_study_id>NP01/2017/MSD3475</org_study_id>
    <nct_id>NCT03813394</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Pembrolizumab Combination in EBER-ISH Positive NPC</brief_title>
  <acronym>2018/00947</acronym>
  <official_title>Phase Ib/II Open-label Study Evaluating the Combination of Bevacizumab Priming With Pembrolizumab in EBER-ISH Positive Nasopharyngeal Carcinoma (NPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, randomized, phase Ib/II open-label study of pembrolizumab (pembro or&#xD;
      MK-3475) with or without bevacizumab in patients with recurrent non-curable or metastatic&#xD;
      nasopharyngeal carcinoma (NPC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of 2 treatment arms. In Treatment Arm A, patients will be treated with&#xD;
      intravenous pembrolizumab alone, 21-day cycle. For Treatment Arm B, patients will receive&#xD;
      intravenous pembrolizumab preceded by an infusion of bevacizumab (Day 1 of 21-day cycle).&#xD;
      Each treatment cycle is 3 weeks. Up to 48 patients will be enrolled in this study in 2&#xD;
      stages. The first stage will consist of 30 patients and the remaining 18 patients will be&#xD;
      added if interim data looks promising.&#xD;
&#xD;
      Eligible patients will be randomized 1:1 into either Treatment Arm A or Arm B. Treatment will&#xD;
      continue until tumor progression, intolerance to treatment, or up to 2 years (32 doses of&#xD;
      pembrolizumab/bevacizumab). For patients who have progressed on pembrolizumab alone, cross&#xD;
      over to Arm B is allowed, with repeat biopsy of the lesions before and 1 week after starting&#xD;
      bevacizumab. Patients who discontinue from the trial will not be replaced.&#xD;
&#xD;
      The study will collect serial samples of tumor tissue and blood to determine the PD&#xD;
      biomarkers of immune activation, in the tumor and systemically, following treatment. This is&#xD;
      expected to provide preliminary evidence for immune stimulation using both pembrolizumab and&#xD;
      bevacizumab in NPC. The tumor biopsies will also present an opportunity to determine the&#xD;
      molecular details of tissue and tumor response to anti-angiogenic therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients will be randomized 1:1 into either Treatment Arm A or Arm B. Treatment will continue until tumor progression, intolerance to treatment, or up to 2 years (32 doses of pembrolizumab/bevacizumab). For patients who have progressed on pembrolizumab alone, cross over to Arm B is allowed, with repeat biopsy of the lesions before and 1 week after starting bevacizumab. Patients who discontinue from the trial will not be replaced.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint of ORR</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of the two treatment arms will be evaluated using the Fisher's exact test. The treatment effect will be quantified via the relative risk estimate and its associated 95% confidence interval (CI).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The secondary endpoint of PFS</measure>
    <time_frame>2 years</time_frame>
    <description>This will be summarized using the Kaplan-Meier survival estimate for each group. As an exploratory analysis, the log-rank test will be used for comparing differences in PFS, with its effect quantified based on hazard ratio and its 95% CI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>This is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded central imaging assessment or death due to any cause, whichever occurs earlier.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Locally Recurrent Cancer</condition>
  <condition>Metastatic Nasopharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous pembrolizumab alone,D8 of 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous pembrolizumab preceded by an infusion of bevacizumab (Day 1 of 21-day cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>-Pembrolizumab in Solution for Injection</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Bevacizumab in Concentrate for Solution&#xD;
Bevacizumab in Concentrate for Solution</description>
    <arm_group_label>Treatment Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Participants are eligible to be included in the study only if all of the following&#xD;
        criteria apply:&#xD;
&#xD;
          1. The participant (or legally acceptable representative if applicable) provides written&#xD;
             consent for the trial.&#xD;
&#xD;
          2. Participants who are at least 21 years of age on the day of signing informed consent&#xD;
             with histologically or cytologically confirmed diagnosis of non-keratinizing&#xD;
             nasopharyngeal carcinoma (NPC) that has recurred at loco regional and/or distant sites&#xD;
             will be enrolled in this study.&#xD;
&#xD;
          3. Have measurable disease based on RECIST 1.1. Lesions situated in a previously&#xD;
             irradiated area are considered measurable if progression has been demonstrated in such&#xD;
             lesions.&#xD;
&#xD;
          4. Have locally or centrally determined EBV-positive NPC by EBV-encoded small RNA in situ&#xD;
             hybridization (EBER in situ hybridization [ISH]) assay. If EBV-positive status has&#xD;
             been previously determined by EBER ISH assay, then no re-testing is required. Note: If&#xD;
             EBV status by EBER ISH assay has not been previously determined, tumor tissue from&#xD;
             archival tissue may be submitted for EBV determination.&#xD;
&#xD;
          5. Received one or more lines of chemotherapy, which must include prior treatment with a&#xD;
             platinum agent and must not be amenable to potentially curative radiotherapy or&#xD;
             surgery.&#xD;
&#xD;
          6. Have provided archival tumor tissue sample of newly obtained core or excisional biopsy&#xD;
             of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE)&#xD;
             tissue blocks are preferred to slides. Newly obtained biopsies are preferred to&#xD;
             archived tissue. Note: If submitting unstained cut slides, newly cut slides should be&#xD;
             submitted to the testing laboratory within 14 days from the date slides are cut.&#xD;
&#xD;
          7. Willingness to donate blood and tissue for mandatory translational research studies.&#xD;
&#xD;
          8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          9. Have an adequate organ function.Specimens must be collected within 10 days prior to&#xD;
             the start of study treatment.&#xD;
&#xD;
         10. A female participant is eligible to participate if she is not pregnant (see Appendix&#xD;
             3), not breastfeeding, and at least one of the following conditions applies: a. Not a&#xD;
             woman of childbearing potential (WOCBP) as defined in Appendix 3 OR b. A WOCBP who&#xD;
             agrees to follow the contraceptive guidance in Appendix 3 during the treatment period&#xD;
             and for at least 120 days after the last dose of study medication.&#xD;
&#xD;
         11. A male participant must agree to use a contraception as detailed in Appendix 3 of this&#xD;
             protocol during the treatment period and for at least 120 days after the last dose of&#xD;
             study treatment and refrain from donating sperm during this period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          1. Has received prior systemic anti-cancer therapy including investigational agents&#xD;
             within 4 weeks prior to randomization. Note: Participants must have recovered from all&#xD;
             AEs to previous therapies to ≤ Grade 1 or baseline. Participants with ≤ Grade 2&#xD;
             neuropathy may be eligible. Note: If participants received major surgery, they must&#xD;
             have recovered adequately from the toxicity and/or complications from the intervention&#xD;
             prior to starting study treatment.&#xD;
&#xD;
          2. Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to first dose of&#xD;
             study treatment.&#xD;
&#xD;
             Note: Participants who have entered the follow-up phase of an investigational study&#xD;
             may participate as long as it has been 4 weeks after the last dose of the previous&#xD;
             investigational agent.&#xD;
&#xD;
          3. Has a condition requiring systemic steroid therapy (&gt; 10 mg daily prednisone&#xD;
             equivalents) or any other form of immunosuppressive therapy within 14 days prior to&#xD;
             the first dose of trial treatment. Inhaled or topical steroids and adrenal replacement&#xD;
             doses &lt;10 mg daily prednisone equivalents are permitted in the absence of active&#xD;
             autoimmune disease. Patients are permitted to use topical, ocular, intra-articular,&#xD;
             intranasal, and inhalational corticosteroids (with minimal systemic absorption).&#xD;
             Physiologic replacement doses of systemic corticosteroids are permitted, even if &lt; or&#xD;
             = 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis&#xD;
             (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g.,&#xD;
             delayedtype hypersensitivity reaction caused by contact allergen) is permitted.&#xD;
&#xD;
          4. Has a known history of active TB (Bacillus Tuberculosis).&#xD;
&#xD;
          5. Has had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, antiCTLA-4&#xD;
             antibody.&#xD;
&#xD;
          6. Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients.&#xD;
&#xD;
          7. Has hypersensitivity to bevacizumab or any of its components.&#xD;
&#xD;
          8. Has received prior radiotherapy within 2 weeks of start of study treatment.&#xD;
             Participants must have recovered from all radiation-related toxicities, not require&#xD;
             corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted&#xD;
             for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease.&#xD;
&#xD;
          9. Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 3 years. Note: Participants with basal cell carcinoma of the skin,&#xD;
             squamous cell carcinoma of the skin, transitional cell carcinoma of urothelial cancer,&#xD;
             or carcinoma in situ (e.g. breast or cervical carcinoma in situ) that have undergone&#xD;
             potentially curative therapy are not excluded.&#xD;
&#xD;
         10. Has known brain metastases or leptomeningeal metastases, whether treated or untreated.&#xD;
             NOTE: Primary nasopharyngeal cancers that directly invade the skull base and extend&#xD;
             into the infratemporal fossa (e) are not regarded as brain metastases and are not&#xD;
             excluded.&#xD;
&#xD;
         11. Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
         12. Has a history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis.&#xD;
&#xD;
         13. Has an active infection requiring systemic therapy.&#xD;
&#xD;
         14. Has uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
         15. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator&#xD;
&#xD;
         16. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         17. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the screening visit through 120 days&#xD;
             after the last dose of trial treatment.&#xD;
&#xD;
         18. A WOCBP who has a positive urine pregnancy test within 72 hours prior to&#xD;
             randomization/allocation (see Appendix 3). If the urine test is positive or cannot be&#xD;
             confirmed as negative, a serum pregnancy test will be required. Note: In the event&#xD;
             that 72 hours have elapsed between the screening pregnancy test and the first dose of&#xD;
             study treatment, another pregnancy test (urine or serum) must be performed and must be&#xD;
             negative in order for subject to start receiving study medication.&#xD;
&#xD;
         19. Has a known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is&#xD;
             required unless mandated by local health authority.&#xD;
&#xD;
         20. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]&#xD;
             reactive or known active Hepatitis C virus (defined as HCV RNA [qualitative] is&#xD;
             detected) infection. Note: No testing for Hepatitis B and Hepatitis C is required&#xD;
             unless mandated by local health authority.&#xD;
&#xD;
         21. Has received a live vaccine within 30 days of prior to the first dose of study drug.&#xD;
             Examples of live vaccines include, but are not limited to, the following: measles,&#xD;
             mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus&#xD;
             Calmette-Guerin (BCG), and typhoid vaccine.&#xD;
&#xD;
        Note: Seasonal influenza vaccines for injection are generally killed virus vaccines and are&#xD;
        allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated&#xD;
        vaccines, and are not allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boon Cher Goh</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boon Cher Goh</last_name>
    <phone>(65) 6779 5555</phone>
    <email>phcgbc@nus.edu.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Ma BB, Hui EP, Chan AT. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci. 2008 Jul;99(7):1311-8. doi: 10.1111/j.1349-7006.2008.00836.x. Epub 2008 May 21.</citation>
    <PMID>18498420</PMID>
  </reference>
  <reference>
    <citation>Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27. Erratum In: J Clin Oncol. 2018 Aug 1;36(22):2360.</citation>
    <PMID>29584545</PMID>
  </reference>
  <reference>
    <citation>Zarrabi K, Fang C, Wu S. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. J Hematol Oncol. 2017 Feb 2;10(1):38. doi: 10.1186/s13045-016-0374-y.</citation>
    <PMID>28153029</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 20, 2019</study_first_submitted>
  <study_first_submitted_qc>January 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2019</study_first_posted>
  <last_update_submitted>April 5, 2019</last_update_submitted>
  <last_update_submitted_qc>April 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Epstein Barr virus</keyword>
  <keyword>Nasopharyngeal cancer</keyword>
  <keyword>Anti-PD1</keyword>
  <keyword>Tumor neoantigens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03813394
org study id: NP01/2017/MSD3475
nct id: NCT03813394
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
This is a single center, randomized, phase Ib/II open-label study of pembrolizumab (pembro or
      MK-3475) with or without bevacizumab in patients with recurrent non-curable or metastatic
      nasopharyngeal carcinoma (NPC).
The study will consist of 2 treatment arms. In Treatment Arm A, patients will be treated with
      intravenous pembrolizumab alone, 21-day cycle. For Treatment Arm B, patients will receive
      intravenous pembrolizumab preceded by an infusion of bevacizumab (Day 1 of 21-day cycle).
      Each treatment cycle is 3 weeks. Up to 48 patients will be enrolled in this study in 2
      stages. The first stage will consist of 30 patients and the remaining 18 patients will be
      added if interim data looks promising.

      Eligible patients will be randomized 1:1 into either Treatment Arm A or Arm B. Treatment will
      continue until tumor progression, intolerance to treatment, or up to 2 years (32 doses of
      pembrolizumab/bevacizumab). For patients who have progressed on pembrolizumab alone, cross
      over to Arm B is allowed, with repeat biopsy of the lesions before and 1 week after starting
      bevacizumab. Patients who discontinue from the trial will not be replaced.

      The study will collect serial samples of tumor tissue and blood to determine the PD
      biomarkers of immune activation, in the tumor and systemically, following treatment. This is
      expected to provide preliminary evidence for immune stimulation using both pembrolizumab and
      bevacizumab in NPC. The tumor biopsies will also present an opportunity to determine the
      molecular details of tissue and tumor response to anti-angiogenic therapy.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: Eligible patients will be randomized 1:1 into either Treatment Arm A or Arm B. Treatment will continue until tumor progression, intolerance to treatment, or up to 2 years (32 doses of pembrolizumab/bevacizumab). For patients who have progressed on pembrolizumab alone, cross over to Arm B is allowed, with repeat biopsy of the lesions before and 1 week after starting bevacizumab. Patients who discontinue from the trial will not be replaced.
primary purpose: Treatment
masking: None (Open Label)
measure: Primary endpoint of ORR
time frame: 2 years
description: Comparison of the two treatment arms will be evaluated using the Fisher's exact test. The treatment effect will be quantified via the relative risk estimate and its associated 95% confidence interval (CI).
measure: The secondary endpoint of PFS
time frame: 2 years
description: This will be summarized using the Kaplan-Meier survival estimate for each group. As an exploratory analysis, the log-rank test will be used for comparing differences in PFS, with its effect quantified based on hazard ratio and its 95% CI.
measure: Progression free survival (PFS)
time frame: 2 years
description: This is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded central imaging assessment or death due to any cause, whichever occurs earlier.
arm group label: Treatment Arm A
arm group type: Experimental
description: Intravenous pembrolizumab alone,D8 of 21-day cycle.
arm group label: Treatment Arm B
arm group type: Experimental
description: Intravenous pembrolizumab preceded by an infusion of bevacizumab (Day 1 of 21-day cycle).
intervention type: Drug
intervention name: pembrolizumab
description: -Pembrolizumab in Solution for Injection
arm group label: Treatment Arm A
arm group label: Treatment Arm B
intervention type: Drug
intervention name: bevacizumab
description: Bevacizumab in Concentrate for Solution
Bevacizumab in Concentrate for Solution
arm group label: Treatment Arm B
criteria: 
gender: All
minimum age: 21 Years
maximum age: 99 Years
healthy volunteers: No
last name: Boon Cher Goh
role: Principal Investigator
affiliation: National University Hospital, Singapore
last name: Boon Cher Goh
phone: (65) 6779 5555
email: phcgbc@nus.edu.sg
facility: 
country: Singapore
citation: Ma BB, Hui EP, Chan AT. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci. 2008 Jul;99(7):1311-8. doi: 10.1111/j.1349-7006.2008.00836.x. Epub 2008 May 21.
PMID: 18498420
citation: Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27. Erratum In: J Clin Oncol. 2018 Aug 1;36(22):2360.
PMID: 29584545
citation: Zarrabi K, Fang C, Wu S. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. J Hematol Oncol. 2017 Feb 2;10(1):38. doi: 10.1186/s13045-016-0374-y.
PMID: 28153029
responsible party type: Sponsor
mesh term: Nasopharyngeal Neoplasms
mesh term: Nasopharyngeal Carcinoma
mesh term: Recurrence
mesh term: Bevacizumab
mesh term: Pembrolizumab
sharing ipd: No